Abstract:Abstract Background The growing discipline of structural systems pharmacology is applied prospectively in this study to predict pharmacological outcomes of antibacterial compounds in Escherichia coli K12. This work builds upon previously established methods for structural prediction of ligand binding pockets on protein molecules and utilizes and expands upon the previously developed genome scale model of metabolism integrated with protein structures (GEM-PRO) for E. coli , structurally accounting for protein complexes. Carefully selected case studies are demonstrated to display the potential for this structural systems pharmacology framework in discovery and development of antibacterial compounds. Results The prediction framework for antibacterial activity of compounds was validated for a control set of well-studied compounds, recapitulating experimentally-determined protein binding interactions and deleterious growth phenotypes resulting from these interactions. The antibacterial activity of fosfomycin, sulfathiazole, and trimethoprim were accurately predicted, and as a negative control glucose was found to have no predicted antibacterial activity. Previously uncharacterized mechanisms of action were predicted for compounds with known antibacterial properties, including (1-hydroxyheptane-1,1-diyl)bis(phosphonic acid) and cholesteryl oleate. Five candidate inhibitors were predicted for a desirable target protein without any known inhibitors, tryptophan synthase β subunit (TrpB). In addition to the predictions presented, this effort also included significant expansion of the previously developed GEM-PRO to account for physiological assemblies of protein complex structures with activities included in the E. coli K12 metabolic network. Conclusions The structural systems pharmacology framework presented in this study was shown to be effective in the prediction of molecular mechanisms of antibacterial compounds. The study provides a promising proof of principle for such an approach to antibacterial development and raises specific molecular and systemic hypotheses about antibacterials that are amenable to experimental testing. This framework, and perhaps also the specific predictions of antibacterials, is extensible to developing antibacterial treatments for pathogenic E. coli and other bacterial pathogens.

Novel prediction of interactive mode between antibiotics and their DNA/protein targets based on the antibiotic structure parameters.

Studies on the Interaction Between Antibiotics and DNA

QSAR Study on the Interactions Between Antibiotic Compounds and DNA by a Hybrid Genetic-Based Support Vector Machine

Investigation of bacterial DNA gyrase Inhibitor classification models and structural requirements utilizing multiple machine learning methods

Prediction of Antibacterial Compounds by Machine Learning Approaches

In silico prediction of drug-target interaction networks based on drug chemical structure and protein sequences

Predicting Antimicrobial Activity of Conjugated Oligoelectrolyte Molecules via Machine Learning

Molecular Substructure-Aware Network for Drug-Drug Interaction Prediction

Antibacterial mechanisms identified through structural systems pharmacology

The Prediction of LptA and LptC Protein-Protein Interactions and Virtual Screening for Potential Inhibitors

Modern Semiempirical Electronic Structure Methods and Machine Learning Potentials for Drug Discovery: Conformers, Tautomers, and Protonation States

Computational prediction of inter-species relationships through omics data analysis and machine learning

Dynamic Profiling and Binding Affinity Prediction of NBTI Antibacterials against DNA Gyrase Enzyme by Multidimensional Machine Learning and Molecular Dynamics Simulations

Prediction of Synergistic Antibiotic Combinations by Graph Learning

Molecular Structure-Based Double-Central Drug-Drug Interaction Prediction

Quantitative Structure - Activity Relationship Model for Prediction of Genotoxic Potential for Quinolone Antibacterials

A multiscale approach to predict the binding mode of metallo beta‐lactamase inhibitors

Machine learning approaches for predicting compounds that interact with therapeutic and ADMET related proteins.

Antibiotic Combinations Prediction Based on Machine Learning to Multicentre Clinical Data and Drug Interaction Correlation.

Using Chemoinformatics, Bioinformatics, and Bioassay to Predict and Explain the Antibacterial Activity of Nonantibiotic Food and Drug Administration Drugs

Antibacterial Activity Prediction Model of Traditional Chinese Medicine Based on Combined Data-Driven Approach and Machine Learning Algorithm: Constructed and Validated